In 2025, Ascentage Pharma conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 98.97a | 78.94a | 64.78a | |
Total Waste Recovered | N/A | N/A | N/A | |
Total Hazardous Waste Generated | 72.15a | 59.25a | 47.91a | |
Non-Hazardous Waste Disposed | N/A | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Ascentage Pharma generated a total of 99 metric tonnes of waste.a
Of this amount, 72.9% of Ascentage Pharma's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.27.1% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, Ascentage Pharma's total waste generation increased by 52.78%, including a 25.37% rise in 2025, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.a
Over the same period, Ascentage Pharma reduced the hazardousness of its waste by 1.43%, with a further 2.87% decline in 2025, suggesting a sustained and meaningful shift toward safer waste profiles and lower environmental impact.a
Overall, Ascentage Pharma is generating more waste but has significantly reduced the share of hazardous materials, suggesting a partial decoupling of volume and toxicity that could reflect more responsible inputs or enhanced treatment.a